Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

VANCOUVER, WASH. AND NEW YORK, OCT. 29, 2025 (GLOBE NEWSWIRE) -- ABSCI (NASDAQ: ABSI), A CLINICAL-STAGE BIOTECH COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE AI, TODAY ANNOUNCED THE COMPANY WILL REPORT BUSINESS UPDATES AND FINANCIAL AND OPERATING RESULTS FOR THE THIRD QUARTER 2025 AFTER MARKET CLOSE ON WEDNESDAY, NOVEMBER 12, 2025.

ABSCI TO REPORT BUSINESS UPDATES AND THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS ON NOVEMBER 12, 2025

VANCOUVER, WASH. AND NEW YORK, OCT. 27, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOTECH COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE AI, TODAY ANNOUNCED THE COMPANY WILL BE PARTICIPATING IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

ABSCI TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

WEBINAR ON DECEMBER 11 TO FEATURE LEADING KOLS IN DERMATOLOGY AND HAIR LOSS ALONGSIDE ABSCI LEADERSHIP PHASE 1/2A TRIAL NOW EXPECTED TO BEGIN IN DECEMBER 2025, AHEAD OF PRIOR GUIDANCE VANCOUVER, WASH. AND NEW YORK, OCT. 15, 2025 (GLOBE NEWSWIRE) -- ABSCI (NASDAQ: ABSI), A CLINICAL-STAGE BIOTECH COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE AI, TODAY ANNOUNCED THE COMPANY WILL HOST A VIRTUAL SEMINAR ON DECEMBER 11, 2025 AT 10:00AM ET FOCUSED ON THE COMPANY'S ABS-201 (ANTI-PRLR) PROGRAM FOR ANDROGENETIC ALOPECIA.

ABSCI TO HOST KOL SEMINAR ON ABS-201 ANDROGENETIC ALOPECIA PROGRAM ON DECEMBER 11, 2025; ANNOUNCES ACCELERATED INITIATION OF PHASE 1/2A TRIAL

PERFORMANCE AND SCALABILITY OF ORACLE CLOUD INFRASTRUCTURE AI INFRASTRUCTURE ENABLES ABSCI TO ACCELERATE BIOLOGICS DESIGN CYCLES AND REDUCE COSTS PERFORMANCE AND SCALABILITY OF ORACLE CLOUD INFRASTRUCTURE AI INFRASTRUCTURE ENABLES ABSCI TO ACCELERATE BIOLOGICS DESIGN CYCLES AND REDUCE COSTS

ABSCI ACCELERATES AI-DRIVEN DRUG DISCOVERY WITH ORACLE AND AMD

WORLD-RENOWNED EXPERTS WILL GUIDE THE CLINICAL DEVELOPMENT OF ABS-201, A THERAPEUTIC ANTIBODY ENTERING CLINICAL TRIALS FOR THE TREATMENT OF ANDROGENETIC ALOPECIA. WORLD-RENOWNED EXPERTS WILL GUIDE THE CLINICAL DEVELOPMENT OF ABS-201, A THERAPEUTIC ANTIBODY ENTERING CLINICAL TRIALS FOR THE TREATMENT OF ANDROGENETIC ALOPECIA.

ABSCI EXPANDS ABS-201 SCIENTIFIC ADVISORY BOARD WITH ADDITION OF LEADING DERMATOLOGY EXPERTS DR. RODNEY SINCLAIR AND DR. DAVID GOLDBERG

VANCOUVER, WASH. AND NEW YORK, AUG. 20, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE AI, TODAY ANNOUNCED THE COMPANY WILL BE PARTICIPATING IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

STRENGTHENED BALANCE SHEET RAISING APPROXIMATELY $64 MILLION IN GROSS PROCEEDS IN JULY 2025; CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS NOW SUFFICIENT TO FUND OPERATIONS INTO THE FIRST HALF OF 2028

ABSCI REPORTS BUSINESS UPDATES AND SECOND QUARTER 2025 FINANCIAL AND OPERATING RESULTS

BARCELONA, SPAIN AND VANCOUVER, WASH., AUG. 07, 2025 (GLOBE NEWSWIRE) -- ALMIRALL (BME: ALM), A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON MEDICAL DERMATOLOGY, AND ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE AI, TODAY ANNOUNCED THE EXPANSION OF THEIR ONGOING AI DRUG DISCOVERY COLLABORATION WITH ALMIRALL'S SELECTION OF A SECOND TARGET AIMED AT DERMATOLOGICAL INDICATIONS.

ALMIRALL AND ABSCI EXPAND AI DRUG CREATION COLLABORATION ADDING A SECOND DERMATOLOGY TARGET

VANCOUVER, WASH. AND NEW YORK, JULY 30, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS WITH GENERATIVE DESIGN, TODAY ANNOUNCED THE COMPANY WILL REPORT BUSINESS UPDATES AND FINANCIAL AND OPERATING RESULTS FOR THE SECOND QUARTER 2025 AFTER MARKET CLOSE ON TUESDAY, AUGUST 12, 2025.

ABSCI TO REPORT BUSINESS UPDATES AND SECOND QUARTER 2025 FINANCIAL AND OPERATING RESULTS ON AUGUST 12, 2025

VANCOUVER, WASH., JULY 24, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI) (ABSCI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING POTENTIAL BREAKTHROUGH THERAPEUTICS DESIGNED WITH GENERATIVE AI, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 16,670,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $3.00 PER SHARE, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS. IN ADDITION, ABSCI HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 2,500,500 SHARES OF ITS COMMON STOCK ON THE SAME TERMS AND CONDITIONS. THE GROSS PROCEEDS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES, ARE EXPECTED TO BE APPROXIMATELY $50 MILLION, EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. ALL OF THE SHARES IN THE OFFERING ARE TO BE SOLD BY ABSCI.

ABSCI ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

VANCOUVER, WASH., JULY 24, 2025 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI) (ABSCI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING POTENTIAL BREAKTHROUGH THERAPEUTICS DESIGNED WITH GENERATIVE AI, ANNOUNCED TODAY THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $50 MILLION OF SHARES OF ITS COMMON STOCK. ABSCI ALSO INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $7.5 MILLION OF SHARES OF ITS COMMON STOCK. ALL OF THE SHARES IN THE PROPOSED OFFERING ARE TO BE SOLD BY ABSCI.

ABSCI ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

VANCOUVER, WASH., JULY 07, 2025 (GLOBE NEWSWIRE) -- ABSCI (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS DESIGNED WITH GENERATIVE AI, TODAY ANNOUNCED THE APPOINTMENT OF VETERAN BIOPHARMACEUTICAL EXECUTIVE MARY SZELA TO ITS BOARD OF DIRECTORS.

Absci Corporation

ABSI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Absci Corporation

ABSI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ABSI